INSIDER
01Overview02Follow the Money03Daily Brief04Live05Congress06Corporate Insiders07Government Money08Political Influence09Institutions10Washington Network11Follow the Power12Disclosure Clock13AI Investigator14Watchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodology
Data sources

Public disclosures only. Scores flag unusual patterns and are not evidence of wrongdoing. Not investment advice.

RH CHAIN…
OverviewFollow the MoneyDaily BriefLiveCongressCorporate InsidersGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodology
01Overview02Follow the Money03Daily Brief04Live05Congress06Corporate Insiders07Government Money08Political Influence09Institutions10Washington Network11Follow the Power12Disclosure Clock13AI Investigator14Watchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodology
OverviewFollow the MoneyDaily BriefLiveCongressCorporate InsidersGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodology
Data sources
SEC FORM 421m ago
HOUSE PTR20m ago
SEC 13F20m ago
ROBINHOOD CHAIN20m ago
SEC FORM 4/Open-market purchaseVerified data

Rieger Jayson bought VRCA

Director, CEO and President · Verrica Pharmaceuticals Inc. · Common Stock

Side
BUY
Value
$400K
Shares
94.3K
Price
$4.24
Executed
Nov 25, 2025
Disclosed
Nov 25, 2025
Disclosure timeline0 days from execution to publication · legal deadline 2 business days
Nov 25 executedNov 25, 2025 disclosed

VRCA · daily

Yahoo Finance chart API
▲Execution▼Disclosure●Material company filing●Other disclosed buy●Other disclosed sellUnofficial public endpoint; daily OHLCV, split-adjusted. Replace with a licensed feed for production.

Insider Score

Experimental signal
52/ 100 · NOTABLE
Methodology →
  • Transaction type+20 / 20

    Open-market purchase

  • Relative size+19 / 25

    $400K reported value · 106.8% of prior position

  • Filing timing0 / 15

    Disclosed 0 business days after execution (deadline: 2)

  • Historical behavior+8 / 15

    First recorded trade by this actor in this security

  • Frequency & clustering+5 / 15

    1 other actor traded the same direction within 14 days

  • Market events0 / 10

    No material company filing within 60 days after the trade

    • The Insider Score measures how far a disclosure deviates from normal filing patterns. A high score is a prompt for research, not evidence of illegal insider trading.

    Other disclosed activity · VRCA

    ScoreActorSecuritySideValueExecutedDisclosedLagSourceEvidence
    30
    RJ
    Rieger JaysonDirector, CEO and President
    VRCAVerrica Pharmaceuticals Inc.
    Open-market purchase
    		BUY$25K
    5,000 sh
    		Aug 17, 2026Aug 18, 2026
    traded Aug 17, 2026
    		+1dSEC FORM 4

    Evidence

    38
    ZD
    Zawitz DavidChief Operating Officer
    VRCAVerrica Pharmaceuticals Inc.
    Open-market purchase
    		BUY$30K
    6,000 sh
    		Aug 17, 2026Aug 18, 2026
    traded Aug 17, 2026
    		+1dSEC FORM 4

    Evidence

    37
    RJ
    Rieger JaysonDirector, CEO and President
    VRCAVerrica Pharmaceuticals Inc.
    Open-market purchase
    		BUY$101K
    20.0K sh
    		Aug 14, 2026Aug 18, 2026
    traded Aug 14, 2026
    		+4dSEC FORM 4

    Evidence

    9
    EL
    Eichenfield LawrenceDirector
    VRCAVerrica Pharmaceuticals Inc.
    Grant or award
    		A—
    16.0K sh
    		Jun 5, 2026Jun 9, 2026
    traded Jun 5, 2026
    		+4dSEC FORM 4

    Evidence

    9
    ND
    Nguyen DiemDirector
    VRCAVerrica Pharmaceuticals Inc.
    Grant or award
    		A—
    16.0K sh
    		Jun 5, 2026Jun 9, 2026
    traded Jun 5, 2026
    		+4dSEC FORM 4

    Evidence

    5
    ZD
    Zawitz DavidChief Operating Officer
    VRCAVerrica Pharmaceuticals Inc.
    Grant or award
    		A—
    171.3K sh
    		Jun 5, 2026Jun 9, 2026
    traded Jun 5, 2026
    		+4dSEC FORM 4

    Evidence

    5
    RJ
    Rieger JaysonDirector, CEO and President
    VRCAVerrica Pharmaceuticals Inc.
    Grant or award
    		A—
    512.3K sh
    		Jun 5, 2026Jun 9, 2026
    traded Jun 5, 2026
    		+4dSEC FORM 4

    Evidence

    46
    ZD
    Zawitz DavidChief Operating Officer
    VRCAVerrica Pharmaceuticals Inc.
    Open-market purchase
    		BUY—
    2,500 sh
    		Nov 25, 2025Nov 25, 2025
    traded Nov 25, 2025
    		+0dSEC FORM 4

    Evidence

    46
    ZD
    Zawitz DavidChief Operating Officer
    VRCAVerrica Pharmaceuticals Inc.
    Open-market purchase
    		BUY$42K
    10.0K sh
    		Nov 25, 2025Nov 25, 2025
    traded Nov 25, 2025
    		+0dSEC FORM 4

    Evidence

    46
    RJ
    Rieger JaysonDirector, CEO and President
    VRCAVerrica Pharmaceuticals Inc.
    Open-market purchase
    		BUY—
    23.6K sh
    		Nov 25, 2025Nov 25, 2025
    traded Nov 25, 2025
    		+0dSEC FORM 4

    Evidence

    Evidence

    Verified data

    Read directly from the primary public document; every field below is as reported by the filer.

    Source

    Document
    SEC Form 4
    Publisher
    U.S. Securities and Exchange Commission (EDGAR)
    Document ID
    0002043558-25-000003
    Machine-readable
    Structured copy

    Timestamps

    Event (reported)
    Nov 25, 2025
    Published
    Nov 25, 2025
    Ingested by INSIDER
    Nov 5, 04:31 UTC
    Last re-read
    Nov 5, 04:31 UTC

    Extracted facts

    Filer
    Rieger Jayson
    Role
    Director, CEO and President
    Transaction
    Open-market purchaseAs filed: “P”
    Asset
    Verrica Pharmaceuticals Inc.
    Ticker
    VRCA
    Shares
    94.3K
    Price per share
    $4.24
    Value
    $400,114
    Execution date (reported)
    Nov 25, 2025
    Owned after transaction
    182.6K shares
    Days from execution to publication
    0

    Calculation

    Value = shares × reported price per share

    • Shares: 94.3K
    • Price: $4.2425

    = $400,114

    What this establishes

    Rieger Jayson filed this Form 4 reporting a open-market purchase of VRCA on Nov 25, 2025. It became public on Nov 25, 2025. The filing establishes the reported transaction and the filer's stated role. It does not establish why the trade was made or what the filer knew.

    Extraction

    Method
    Form 4 XML
    Confidence
    1.00
    Director, CEO and President
    Rieger Jaysoncik:0002043558
    Issuer
    Verrica Pharmaceuticals Inc.cik:0001660334

    Revision history · 0

    No field has changed since this record was first ingested.

    Company events

    No records

    No material filings recorded for this issuer.